Ftse Mib
33.736,40
0,00%
DAX
17.896,50
-0,14%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
59.631,71
0,86%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Allarity Therapeutics Inc (ALLR) Allarity Therapeutics Inc (ALLR) Notizie

Allarity Therapeutics Inc

ALLR
1,1603
-0,2097 (-15,31%)
03 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/5/202414:00GLOBEAllarity Therapeutics’ Stenoparib Shows Clear Clinical..
29/4/202413:00GLOBEAllarity Therapeutics Regains Compliance with NASDAQ Minimum..
17/4/202415:10GLOBEAllarity Therapeutics Receives NASDAQ-Approved Extension to..
04/4/202415:15GLOBEAllarity Therapeutics Announces 1-for-20 Reverse Stock Split
27/3/202413:30GLOBEAllarity Therapeutics Makes Strategic Pivot to Focus Solely..
25/3/202412:30GLOBEAllarity Therapeutics Receives Extension from Nasdaq..
08/3/202414:38EDGAR2Form 8-K - Current report
08/3/202413:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/3/202413:15GLOBEAllarity Therapeutics Reports Full Year 2023 Financial..
08/3/202403:45EDGAR2Form DEF 14A - Other definitive proxy statements
04/3/202422:05EDGAR2Form 8-K - Current report
01/3/202415:21EDGAR2Form 8-K - Current report
28/2/202412:00GLOBEAllarity Therapeutics to Present at Biomarkers 2024
23/2/202422:09EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
14/2/202415:03EDGAR2Form 8-K - Current report
02/2/202423:03EDGAR2Form D - Notice of Exempt Offering of Securities
01/2/202422:40EDGAR2Form 8-K - Current report
26/1/202423:07EDGAR2Form PRE 14A - Other preliminary proxy statements
25/1/202423:24EDGAR2Form 8-K - Current report
19/1/202423:29EDGAR2Form 8-K - Current report
15/12/202323:00EDGAR2Form S-1/A - General form for registration of securities..
12/12/202312:00GLOBEAllarity Therapeutics Announces Thomas Jensen as Interim CEO..
11/12/202312:30EDGAR2Form 8-K - Current report
06/12/202323:00EDGAR2Form 8-K - Current report
06/12/202314:30EDGAR2Form S-1/A - General form for registration of securities..
05/12/202313:30EDGAR2Form 8-K - Current report
05/12/202313:30GLOBEAllarity’s Early Phase 2 Stenoparib Data Indicates Clinical..
17/11/202323:01EDGAR2Form 8-K - Current report
13/11/202314:35EDGAR2Form 8-K - Current report
02/11/202322:00EDGAR2Form S-3 - Registration statement under Securities Act of..
31/10/202314:30EDGAR2Form S-1 - General form for registration of securities under..
30/10/202322:00EDGAR2Form 8-K - Current report
23/10/202323:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
17/10/202323:00EDGAR2Form S-3/A - Registration statement under Securities Act of..
10/10/202323:00EDGAR2Form S-3 - Registration statement under Securities Act of..
02/10/202313:00GLOBEAllarity Therapeutics to Present at Biomarkers Europe 2023
27/9/202322:30EDGAR2Form 8-K - Current report
15/9/202314:45EDGAR2Form 8-K - Current report
30/8/202322:05GLOBEPLOS ONE Publishes Data on Allarity Therapeutics’ DRP®..
14/8/202321:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202314:15EDGAR2Form 8-K - Current report
31/7/202312:00GLOBEAllarity Therapeutics and FivepHusion Announce Collaboration..
27/7/202322:01EDGAR2Form 8-K - Current report
24/7/202312:00GLOBEAllarity Therapeutics Strengthens Board of Directors with..
17/7/202323:10EDGAR2Form 8-K - Current report
11/7/202322:05EDGAR2Form 8-K - Current report
07/7/202322:30EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
06/7/202312:05EDGAR2Form 8-K - Current report
06/7/202312:00GLOBEAllarity Therapeutics, Inc. Announces Pricing of $11 Million..
05/7/202322:31EDGAR2Form 8-K - Current report
Apertura: 3,04 Min: 1,14 Max: 3,46
Chiusura: 1,37

La tua Cronologia

NASDAQ
ALLR
Allarity Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network